文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Evolution of Immunotherapy for Ovarian Cancer from a Bird's-Eye Perspective: A Text-Mining Analysis of Publication Trends and Topics.

作者信息

Jiang Guangyi, Hong Junjie, Shao Feng, Wen Qiang, Cheng Feng, Yu Tunan, Zhu Jianqing

机构信息

Department of Gynecological Oncology, Cancer Hospital of University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.

Department of General Surgery, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, China.

出版信息

Front Oncol. 2022 Feb 24;12:795129. doi: 10.3389/fonc.2022.795129. eCollection 2022.

DOI:10.3389/fonc.2022.795129
PMID:35280816
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8907843/
Abstract

OBJECTIVES: Ovarian tumors are among the most prominent gynecological malignancies and have a poor prognosis. Immunotherapy has undergone incredible progress in the past two decades. Our study aimed to use a bibliometric approach to identify research trends in ovarian cancer immunotherapy. METHODS: Literature on this topic published from 2000-2020 was retrieved from the Web of Science Core Citation database and analyzed using the bibliometric analysis software VOSviewer and CiteSpace. RESULTS: A total of 1729 articles on ovarian cancer immunotherapy published from January 2000 to December 2020 were identified. The number of published articles increased each year, from 40 in 2000 to 209 in 2020. These publications were from 61 countries, and the USA showed a dominant position in publication output, total citations, and average number of citations per paper. Co-citation networks revealed 14 subtopics. 'PD-L1 expression,' 'tumor reactive til,' and 'parp inhibitor' are the current potential subtopics. Furthermore, we determined research trends according to the timeline analysis. CONCLUSION: Our study exhaustively describes the development and summarizes the research trends of ovarian cancer immunotherapy over the past 20 years.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4151/8907843/9a3427e256e1/fonc-12-795129-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4151/8907843/7fdd5cc9e985/fonc-12-795129-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4151/8907843/329c3870947c/fonc-12-795129-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4151/8907843/f60d5ce3d469/fonc-12-795129-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4151/8907843/e58f728ff2d6/fonc-12-795129-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4151/8907843/79dfc9ff6200/fonc-12-795129-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4151/8907843/5d6b44e4e202/fonc-12-795129-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4151/8907843/9a3427e256e1/fonc-12-795129-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4151/8907843/7fdd5cc9e985/fonc-12-795129-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4151/8907843/329c3870947c/fonc-12-795129-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4151/8907843/f60d5ce3d469/fonc-12-795129-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4151/8907843/e58f728ff2d6/fonc-12-795129-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4151/8907843/79dfc9ff6200/fonc-12-795129-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4151/8907843/5d6b44e4e202/fonc-12-795129-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4151/8907843/9a3427e256e1/fonc-12-795129-g007.jpg

相似文献

[1]
Evolution of Immunotherapy for Ovarian Cancer from a Bird's-Eye Perspective: A Text-Mining Analysis of Publication Trends and Topics.

Front Oncol. 2022-2-24

[2]
Bibliometric study of immunotherapy for hepatocellular carcinoma.

Front Immunol. 2023

[3]
Bibliometric and visualized analysis of ocular drug delivery from 2001 to 2020.

J Control Release. 2022-5

[4]
Research trends on anti-PD-1/PD-L1 immunotherapy for esophageal cancer: A bibliometric analysis.

Front Oncol. 2022-11-17

[5]
Research hotspots and trends on spinal cord stimulation for pain treatment: a two-decade bibliometric analysis.

Front Neurosci. 2023-5-25

[6]
Knowledge mapping and current trends of immunotherapy for prostate cancer: A bibliometric study.

Front Immunol. 2022

[7]
Emerging trends and research foci in allergic rhinitis immunotherapy from 2002 to 2021: a bibliometric and visualized study.

Am J Transl Res. 2022-7-15

[8]
Global research trends on anti-PD-1/anti-PD-L1 immunotherapy for triple-negative breast cancer: A scientometric analysis.

Front Oncol. 2023-1-11

[9]
Knowledge mapping and visualization of trends in immunotherapy for ovarian cancer over the past five years: a bibliometric analysis.

Front Immunol. 2024

[10]
Research Hotspots and Trends of Peripheral Nerve Injuries Based on Web of Science From 2017 to 2021: A Bibliometric Analysis.

Front Neurol. 2022-5-20

引用本文的文献

[1]
Diagnostic, prognostic, and immunological roles of CDSN in ovarian cancer.

Heliyon. 2024-6-21

[2]
Analysis of research trends (2014-2023) on oxidative stress and male fertility based on bibliometrics and knowledge graphs.

Front Endocrinol (Lausanne). 2024

[3]
Bibliometric analysis of publication trends and topics of influenza-related encephalopathy from 2000 to 2022.

Immun Inflamm Dis. 2023-9

[4]
Immunotherapy improves disease prognosis by affecting the tumor microenvironment: A bibliometric study.

Front Immunol. 2022

[5]
Bibliometric analysis of global research trends on pyroptosis in lung disease.

Front Immunol. 2022

[6]
Emerging trends and hot spots in autoimmune thyroiditis research from 2000 to 2022: A bibliometric analysis.

Front Immunol. 2022

本文引用的文献

[1]
Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA).

J Clin Oncol. 2021-11-20

[2]
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.

Lancet Oncol. 2021-7

[3]
Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39).

J Clin Oncol. 2021-6-10

[4]
Prognostic impact of tumor-infiltrating lymphocytes in high grade serous ovarian cancer: a systematic review and meta-analysis.

Ther Adv Med Oncol. 2020-10-31

[5]
Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant.

Front Immunol. 2020

[6]
Understanding and addressing barriers to successful adenovirus-based virotherapy for ovarian cancer.

Cancer Gene Ther. 2021-5

[7]
Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment.

BMC Cancer. 2020-8-10

[8]
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study.

Lancet Oncol. 2020-8-6

[9]
An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors.

J Immunother Cancer. 2020-8

[10]
Safety and Clinical Activity of Atezolizumab Plus Bevacizumab in Patients with Ovarian Cancer: A Phase Ib Study.

Clin Cancer Res. 2020-11-1

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索